CLOXACILLIN CAPSULE 250MG contains: Cloxacillin Sodium equivalent to
Cloxacillin 250 mg.
Capsule Colour: Orange/Black
Capsule Size: #2
Granules Colour: White
CLOXACILLIN CAPSULE 500MG contains: Cloxacillin Sodium equivalent to
Cloxacillin 500 mg.
Capsule Colour: Amethyst/Black
Capsule Size: #0
Granules Colour: White
Marking: "DYNA" & Company Logo
Cloxacillin is a bactericidal antibiotic which inhibits bacterial cell wall
synthesis, probably by acylation of membrane-bound transpeptidase enzymes.
This prevents cross-linkage of peptidoglycan chains which is necessary for
bacterial cell wall strength and rigidity. Also, cell division and growth
are inhibited and lysis of susceptible bacteria frequently occurs. Rapidly
dividing bacteria are most susceptible to penicillin group of antibiotics.
Cloxacillin is resistant to staphylococcal penicillinase. It has an
antibacterial spectrum similar to that of methicillin.
Cloxacillin sodium is incompletely absorbed from the gastrointestinal tract
after oral administration, and absorption is further reduced by the presence
of food in the stomach. After an oral dose of 500 mg, a peak plasma
concentration of 7 to 14 µg per ml is obtained in fasting subjects in 1 to 2
hours. Absorption is more complete when given by intramuscular injection and
peak plasma concentrations of about 15 g per ml have been observed 30
minutes after a dose of 500 mg. Doubling the dose can double the plasma
concentration. About 94% of cloxacillin in the circulation are bound to
plasma proteins. Cloxacillin has been reported to have a plasma half-life of
approximately 0.5 hours in healthy subjects. The half-life is prolonged in
neonates. Cloxacillin diffuses across the placenta into the foetal
circulation and is excreted in breast milk. There is little diffusion into
the CFS except when the meninges are inflamed. Therapeutic concentrations
can be achieved in pleural and synovial fluids and in bone. Cloxacillin is
metabolised to a limited extent, and the unchanged drug and metabolites are
excreted in the urine by glomelurar filtration and renal tubular secretion.
About 35% of an oral dose are excreted in the urine and up to 10% in the
bile. Serum concentrations are enhanced if probenecid is given
Infections caused by staphylococci resistant to benzylpenicillin, including
infections of the skin and soft tissues, bones and joints, respiratory tract
and urinary tract; otitis media, endocarditis, septicaemia and meningitis.
It is also used for mixed streptococcal and staphylococcal infections when
the staphylococci are penicillin-resistant. It is also used for the
prophylaxis of staphylococcal infections during major surgical procedures,
particularly in cardiothoracic and orthopaedic surgery.
Adults 250 - 500 mg every 6 hours daily.
Children 50 - 100 mg per kg body-weight daily in divided doses.
* Patient should continue medicine for full course of treatment.
* Take medicine on empty stomach.
* Reduced dosage is required in patients with impaired renal function.
Patients hypersensitive to cloxacillin or a history of allergic to
penicillin group of drugs.
WARNING AND PRECAUTIONS
Patients hypersensitive to other penicillin or cephalosporins or
penicillamine may be hypersensitive to cloxacillin. If a skin rash occurs,
treatment should be discontinued.
Probenecid impairs renal excretion. Reduces anticoagulant effect.
PREGNANCY AND LACTATION
Risk-benefit must be considered when given to pregnant women and during
SIDE EFFECTS/ADVERSE REACTIONS
Side effects such as diarrhoea, nausea and heartburn may occur following
administration by mouth. Sensitivity reactions may occur to patients
hypersensitive to the drug. The most common side effects are allergic
reaction and of these, skin rashes occur most frequently.
SYMPTOMS AND TREATMENT OF OVERDOSE
Overdosage may cause GIT disturbances, reversible impairment of liver
function and diarrhoea. Treatment include stop antibiotic treatment, treat
GIT distress by giving milk every 3 hours alternating with bismuth
subcarbonate 5 g every 3 hours.
Problems of overdosage are unlikely to be encountered. Gross overdosage will
produce very high urinary concentration, more so after parenteral
administration. Problems are unlikely if adequate fluid intake and urinary
output are maintained; however crystalluria is a possibility. More specific
measures may be necessary in patients with impaired renal function; the
antibiotic is removed by haemodialysis.
CLOXACILLIN CAPSULE 250MG
- Plastic containers of 20's and 1000's (For EXPORT/TENDER Only).
- Blister packs of 50 x 10's and 100 x 10's.
CLOXACILLIN CAPSULE 500MG
- Plastic container of 500's (For EXPORT/TENDER Only).
- Blister packs of 10 x 10's and 50 x 10's.
3 years from the date of manufacture.
KEEP OUT OF REACH OF CHILDREN
Keep Container Tightly Closed
Store In A Dry Place Below 25°C
Protect From Light